search
Back to results

The Effects of Oral Vitamin D Supplementation on the Prevention of Peritoneal Dialysis-related Peritonitis

Primary Purpose

Peritoneal Dialysis-associated Peritonitis, Vitamin D Deficiency

Status
Completed
Phase
Phase 2
Locations
China
Study Type
Interventional
Intervention
Cholecalciferol (2000iu qd)
Routine therapy for PD
Sponsored by
Peking University First Hospital
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Peritoneal Dialysis-associated Peritonitis focused on measuring Cholecalciferol, Peritoneal dialysis, Peritonitis

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Medically stable and receiving peritoneal dialysis (PD) for>1 months
  2. Age at least 18 years.
  3. Serum 25(OH)D<75nmol/l (30ng/ml)
  4. Adequate dialysis on evaluation, weekly Kt/V ≥ 1.5 and no clinical uremic symptoms

Exclusion Criteria:

  1. Receive Vitamin D2/D3 or drugs known to alter serum 25-hydroxyvitamin D (25(OH)D) levels during the previous 12 months;
  2. History of allergic reaction to Cholecalciferol;
  3. Current or past malignant disease, active hepatitis or hepatic failure, acute systemic infection, active autoimmune diseases, severe digestive malabsorption or eating disorder, HIV/AIDS;
  4. A high probability (assessed by the recruiting physician) of receiving a kidney transplant or transferring to hemodialysis (HD) or drop-out due to socioeconomic causes within 6 months;
  5. Pregnant or breastfeeding;

Sites / Locations

  • Peking University First Hospital

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

Treatment group

Control group

Arm Description

Patients will receive oral Cholecalciferol (2000IU qd) apart from routine therapy for PD

Patients randomized to the placebo group will receive routine therapy for PD.

Outcomes

Primary Outcome Measures

Recruitment rate of the trial
Recruitment rate of patients screened for the trial measured by percentage.
Retention rate of the trial
Retention rate of included patients in the trial measured by percentage.
Adherence rate of the trial
Percentage of participants adherent to the dosing regimen of vitamin D in the trial.
Incidence of adverse events
Incidence of adverse events measured by number of events per patient-month
Change in serum 25(OH)D level
Change in serum 25(OH)D level between baseline and 12 months measured by ng/ml.

Secondary Outcome Measures

Difference in risk of a subsequent peritonitis measured by Hazard Ratio.
Risk of a subsequent peritoneal dialysis related peritonitis in the interventional group compared with the control group measured by Hazard Ratio.
Probability of participants who recovered after subsequent peritoneal dialysis related peritonitis.
Probability of participants who recovered after peritoneal dialysis-related peritonitis measured by percentage.
Risk of participants who died because of subsequent peritoneal dialysis related peritonitis.
Risk of participants who died because of peritoneal dialysis-related peritonitis measured by percentage.
Risk of participants who are transitioned to hemodialysis because of subsequent peritoneal dialysis related peritonitis.
Risk of patients who are transferred to hemodialysis because of peritoneal dialysis related peritonitis measured by percentage.

Full Information

First Posted
October 10, 2016
Last Updated
August 12, 2021
Sponsor
Peking University First Hospital
search

1. Study Identification

Unique Protocol Identification Number
NCT03264625
Brief Title
The Effects of Oral Vitamin D Supplementation on the Prevention of Peritoneal Dialysis-related Peritonitis
Official Title
The Effects of Oral Vitamin D Supplementation on the Prevention of Peritoneal Dialysis-related Peritonitis
Study Type
Interventional

2. Study Status

Record Verification Date
August 2021
Overall Recruitment Status
Completed
Study Start Date
September 30, 2017 (Actual)
Primary Completion Date
May 28, 2021 (Actual)
Study Completion Date
July 30, 2021 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Peking University First Hospital

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
This is a pilot randomized, controlled trial of Vitamin D supplementation in patients on peritoneal dialysis to determine the feasibility of a future full-scale RCT exploring if oral administration of vitamin D3 could reduce the risk of subsequent Peritoneal dialysis-related (PD-related) peritonitis. Aims of the study: Aim 1: To determine the feasibility of oral vitamin D supplementation among PD patients who have recovered from a recent episode of peritonitis. Aim 2: To examine the effect of vitamin D supplementation on the risk for peritonitis among patients on peritoneal dialysis.
Detailed Description
Patients will be screened for eligibility one month after the onset of PD-related peritonitis, those who meet the inclusion criteria will be enrolled in this study. All consenting participants will be randomized into the vitamin D treatment group or the control group, general information and baseline biochemistry data would be collected. Patients in the treatment group will be treated with oral Cholecalciferol (2000IU/day) apart from routine treatment for PD. Those in the control group will receive routine treatment for PD. Both groups will be followed for 12 months. During the observational period, any onset of subsequent peritonitis will be recorded, serum 25(OH)D, biochemical indices will be measured every 3 months. Follow up would take place frequently, any outcome events would be recorded. Aims and hypotheses: Aim 1: To determine the feasibility of oral vitamin D supplementation among PD patients who have recovered from a recent episode of peritonitis. Hypothesis1: A large、full-scale randomized controlled trail on the effects of oral vitamin D on the risk for peritonitis among PD patients is feasible. Aim 2: To examine the effect of vitamin D supplementation on the risk for peritonitis among patients on peritoneal dialysis. Hypothesis 2: Oral supplementation of vitamin D will reduce the risk of subsequent peritoneal dialysis.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Peritoneal Dialysis-associated Peritonitis, Vitamin D Deficiency
Keywords
Cholecalciferol, Peritoneal dialysis, Peritonitis

7. Study Design

Primary Purpose
Prevention
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
60 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Treatment group
Arm Type
Experimental
Arm Description
Patients will receive oral Cholecalciferol (2000IU qd) apart from routine therapy for PD
Arm Title
Control group
Arm Type
Placebo Comparator
Arm Description
Patients randomized to the placebo group will receive routine therapy for PD.
Intervention Type
Drug
Intervention Name(s)
Cholecalciferol (2000iu qd)
Other Intervention Name(s)
Natural Vitamin D3
Intervention Description
Patients will receive oral Cholecalciferol (2000IU qd) apart from routine therapy for PD
Intervention Type
Other
Intervention Name(s)
Routine therapy for PD
Intervention Description
Patients randomized to the placebo group will receive routine therapy for PD.
Primary Outcome Measure Information:
Title
Recruitment rate of the trial
Description
Recruitment rate of patients screened for the trial measured by percentage.
Time Frame
From date of randomization until 1 year after the randomization of last participant.
Title
Retention rate of the trial
Description
Retention rate of included patients in the trial measured by percentage.
Time Frame
From date of randomization until 1 year after the randomization of last participant
Title
Adherence rate of the trial
Description
Percentage of participants adherent to the dosing regimen of vitamin D in the trial.
Time Frame
From date of randomization until 1 year after the randomization of last participant.
Title
Incidence of adverse events
Description
Incidence of adverse events measured by number of events per patient-month
Time Frame
From date of randomization until 1 year after the randomization of last participant.
Title
Change in serum 25(OH)D level
Description
Change in serum 25(OH)D level between baseline and 12 months measured by ng/ml.
Time Frame
From date of randomization until 1 year after the randomization of last participant
Secondary Outcome Measure Information:
Title
Difference in risk of a subsequent peritonitis measured by Hazard Ratio.
Description
Risk of a subsequent peritoneal dialysis related peritonitis in the interventional group compared with the control group measured by Hazard Ratio.
Time Frame
From date of randomization until the date of subsequent peritonitis, assessed up to 1 year.
Title
Probability of participants who recovered after subsequent peritoneal dialysis related peritonitis.
Description
Probability of participants who recovered after peritoneal dialysis-related peritonitis measured by percentage.
Time Frame
From date of randomization until the date of documented death, assessed up to 1 year.
Title
Risk of participants who died because of subsequent peritoneal dialysis related peritonitis.
Description
Risk of participants who died because of peritoneal dialysis-related peritonitis measured by percentage.
Time Frame
From date of randomization until the date of documented death, assessed up to 1 year.
Title
Risk of participants who are transitioned to hemodialysis because of subsequent peritoneal dialysis related peritonitis.
Description
Risk of patients who are transferred to hemodialysis because of peritoneal dialysis related peritonitis measured by percentage.
Time Frame
From date of randomization until the date of documented transition to hemodialysis because of peritoneal dialysis related peritonitis, assessed up to 1 year.

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Medically stable and receiving peritoneal dialysis (PD) for>1 months Age at least 18 years. Serum 25(OH)D<75nmol/l (30ng/ml) Adequate dialysis on evaluation, weekly Kt/V ≥ 1.5 and no clinical uremic symptoms Exclusion Criteria: Receive Vitamin D2/D3 or drugs known to alter serum 25-hydroxyvitamin D (25(OH)D) levels during the previous 12 months; History of allergic reaction to Cholecalciferol; Current or past malignant disease, active hepatitis or hepatic failure, acute systemic infection, active autoimmune diseases, severe digestive malabsorption or eating disorder, HIV/AIDS; A high probability (assessed by the recruiting physician) of receiving a kidney transplant or transferring to hemodialysis (HD) or drop-out due to socioeconomic causes within 6 months; Pregnant or breastfeeding;
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Jie Dong
Organizational Affiliation
Peking Universiy First Hospital
Official's Role
Study Director
Facility Information:
Facility Name
Peking University First Hospital
City
Beijing
Country
China

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
26224791
Citation
Pi HC, Ren YP, Wang Q, Xu R, Dong J. Serum 25-Hydroxyvitamin D Level Could Predict the Risk for Peritoneal Dialysis-Associated Peritonitis. Perit Dial Int. 2015 Dec;35(7):729-35. doi: 10.3747/pdi.2014.00177. Epub 2015 Jul 29.
Results Reference
background
PubMed Identifier
22798536
Citation
Armas LA, Andukuri R, Barger-Lux J, Heaney RP, Lund R. 25-Hydroxyvitamin D response to cholecalciferol supplementation in hemodialysis. Clin J Am Soc Nephrol. 2012 Sep;7(9):1428-34. doi: 10.2215/CJN.12761211. Epub 2012 Jul 12.
Results Reference
background
PubMed Identifier
31779675
Citation
Zhang YH, Xu X, Pi HC, Yang ZK, Johnson DW, Dong J. The effects of oral vitamin D supplementation on the prevention of peritoneal dialysis-related peritonitis: study protocol for a randomized controlled clinical trial. Trials. 2019 Nov 28;20(1):657. doi: 10.1186/s13063-019-3784-7.
Results Reference
derived

Learn more about this trial

The Effects of Oral Vitamin D Supplementation on the Prevention of Peritoneal Dialysis-related Peritonitis

We'll reach out to this number within 24 hrs